You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

Authors

  • Anne W J Martens Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The NetherlandsDepartment of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Susanne R Janssen Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Ingrid A M Derks Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Homer C Adams III Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Liat Izhak Janssen Pharmaceutical Companies of Johnson and Johnson, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Roel van Kampen Department of Internal Medicine, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands PubMed articlesGoogle scholar articles
  • Sanne H Tonino Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Eric Eldering Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Gerritje J W van der Windt Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, The NetherlandsDepartment of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Arnon P Kater Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles

Citation

Martens AWJ, Janssen SR, Derks IAM, et al
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Journal for ImmunoTherapy of Cancer 2020;8:e000218. doi: 10.1136/jitc-2019-000218
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.